| Biomarker ID | 283 |
| PMID | 18543251 |
| Year | 2008 |
| Biomarker | Myosin VI (MYO6) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Gap junction degradation,Gap junction trafficking and regulation, Glutamate binding and activation of AMPA receptors and synaptic plasticity,Membran trafficking,Transmission across chemical synapses |
| Experiment | Tumor and adjacent normal prostate tissues |
| Type of Biomarker | Diagnostic |
| Cohort | 15 patients having radical prosteactomies were chosen for the study. Tumor and adjacent normal prostate tissues were analysed. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Immunohistochemical |
| Clinical | No |
| Remarks | Molecular alterations associated with the Golgi apparatus may take place during prostate carcinogenesis. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MYO6 |